Allogeneic hematopoietic stem cell transplantation for sickle cell disease in children
HAYES, Inc.
Record ID 32016000767
English
Authors' recommendations:
Purpose of Technology: Allogeneic hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD) involves transplantation of allogeneic hematopoietic stem cells from a human leukocyte antigen (HLA)-matched donor. SCD is a genetic disorder characterized by the presence of abnormal hemoglobin known as hemoglobin S. Patients with SCD have abnormally shaped red blood cells, anemia, and often develop severe pain, organ dysfunction, and premature death. HSCT is the only treatment for SCD with a curative intent. Relevant Questions: Does allogeneic HSCT improve disease symptoms and prolong survival in pediatric and young adult patients with SCD? Is allogeneic HSCT equivalent or superior to standard SCD treatments, including hydroxyurea or chronic transfusions in pediatric and young adult patients? Is allogeneic HSCT for SCD in pediatric and young adult patients safe? Have definitive patient selection criteria been established for
allogeneic HSCT for SCD in pediatric and young adult patients?
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=38806
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Anemia, Sickle Cell
- Child
- Hematopoietic Stem Cell Transplantation
- Transplantation Conditioning
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.